Analysis of Wait Times and Costs During the Peri-Diagnostic Period for Non-Small Cell Lung Cancer

Lung Cancer

Volumn 72, Issue 1, 2011, Pages 125-131

  Cheung, Winson Y ^a   Butler, James R ^b   Kliewer, Erich V ^c,d   Demers, Alain A ^c,d   Musto, Grace ^c   Welch, Stephen ^e   Sivananthan, Gokulan ^e   Navaratnam, Sri ^e  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^c Epidemiology and Cancer Registry   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e CANCERCARE MANITOBA   (Canada)

Author keywords

Costs; Diagnostic delays; Economic; Lung Cancer; NSCLC

Indexed keywords

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BONE MARROW BIOPSY; BRONCHOSCOPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINOSCOPY; MEDICAL SERVICE; PRIORITY JOURNAL; THORAX RADIOGRAPHY; WAIT TIME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DATABASE MANAGEMENT SYSTEMS; FEMALE; HEALTH SERVICES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 79952190221     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.08.001     Document Type: Article

References (31)

1. Jemal A., Siegel R., Ward E., Hao Y.P., Xu J., Murray T., et al. Cancer Statistics 2008. CA Cancer J Clin 2008, 58:71-96.
2. Jemal A., Thun M.J., Ries L.A.G., How H.L., Weir H.K., Center M.M., et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008, 100:1672-1694.
3. Adebonojo S.A., Bowser A.N., Moritz D.M., Corcoran P.C. Impact of revised stage classification of lung cancer on survival. Chest 1999, 115(6):1507-1513.
4. van Rens M.T., de la Riviere A.B., Elbers H.R., van Den Bosch J.M. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 2000, 117(2):374-379.
5. Burgess C.C., Ramirez A.J., Richards M.A., Love S.B. Who and what influences delayed presentation in breast cancer? Br J Cancer 1998, 77:1343-1348.
6. Paterson W.G., Depew W.T., Pare P., Petrunia D., Switzer C., Veldhuyzen van Zanten S.J., et al. Canadian consensus on medically acceptable wait times for digestive health care. Can J Gastroenterol 2006, 20:411-423.
7. Lewis N.R., LeJeune I., Baldwin D.R. Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway. Br J Cancer 2005, 93:905-908.
8. Liberman M., Liberman D., Sampalis J.S., Mulder D.S. Delays to surgery in non-small cell lung cancer. Can J Surg 2006, 49(1):31-36.
9. Hillner B.E., McDonald M.K., Desch C.E., Smith T.J., Penberthy L.T., Maddox P., Retchin S.M. Costs of care associated with non-small cell lung cancer in a commercially insured cohort. J Clin Oncol 1998, 16:1420-1424.
10. Kutikova L., Bowman L., Chang S., Long S.R., Obasaju C., Crown W.H. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 2005, 50:143-154.
11. Bordeleau L. Pharmacoeconomics of systemic therapies for lung cancer. Treat Respir Med 2006, 5:129-141.
12. Bordeleau L., Goodwin P.J. Economic issues in lung cancer. Semin Respir Crit Care Med 2000, 21:375-384.
13. Plosker G.L., Hurst M. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer. Pharmacoeconomics 2001, 19:1111-1134.
14. Holmes J., Dunlop D., Hemmett L., Sharplin P., Bose U. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer. Pharmacoeconomics 2004, 22:581-589.
15. Szczepura A. Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer. Lung Cancer 2002, 38:S21-S28.
16. Zabora J., Brintzenhofeszoc K., Curbow B., Hooker C., Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology 2001, 10:19-28.
17. Carlsen K., Jensen A.B., Jacobsen E., Krasnik M., Johansen C. Psychosocial aspects of lung cancer. Lung Cancer 2005, 47:293-300.
18. Institute for Health Economics, A National List of Provincial Costs for Health Care: Canada 1997/8, Ver.1.0, 10 July 2000, Institute of Health Economics, Alberta, Canada, Table 12-5, p.55.
19. Canadian Institute for Health Information, Hospital Financial Performance Indicators, 1999-2000 to 2002-2003, Canadian Institute for Health Information, Ontario, Canada, 2004, Figure 8, p.29.
20. Rivera M.P., Detterbeck F., Mehta A.C. Diagnosis of lung cancer: the guidelines. Chest 2003, 123(1S):129S-136S.
21. Silvestri G.A., Tanoue L.T., Margolis M.L., Barker J., Detterbeck F. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003, 123:147S-156S.
22. Myrdal G., Lambe M., Hillerdal G., Lamberg K., Agustsson T., Stahle E. Effect of delays on prognosis in patients with non-small cell lung cancer. Thorax 2004, 59:45-49.
23. Salomaa E.R., Sallinen S., Hiekkanen H., Liippo K. Delays in the diagnosis and treatment of lung cancer. Chest 2005, 128:2282-2288.
24. Comber H., Cronin D.P., Deady S., Lorcain P.O., Riordan P. Delays in treatment in the cancer services: impact on cancer stage and survival. Ir Med J 2005, 98:238-239.
25. van den Bergh K.A., Essink-Bot M.L., Bunge E.M., Scholten E.T., Prokop M., van Iersel Ca, et al. Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial). Cancer 2008, 113:396-404.
26. Walsh S., Bruce C., Bennington S., Ravi S. The fourteen day rule and colorectal cancer. Ann R Coll Surg Engl 2002, 84:386-388.
27. Robinson D., Bell C.M., Moller H., Basnett I. Effect of the UK government's 2-week target on waiting times in women with breast cancer in southwest England. Br J Cancer 2003, 89:492-496.
28. Leighl N.B., Tsao W.S., Zawisza D.L., Nematollahi M., Shepherd F.A. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer 2006, 51:115-121.
29. Dedes K.J., Szucs T.D., Bodis S., Joerger M., Lowy A., Russi E.W. Management and costs of treating lung cancer patients in a university hospital. Pharmacoeconomics 2004, 22:435-444.
30. Axford A.T., Askill C., Jones A.J. Virtual multidisciplinary teams for cancer care. J Telemed Telecare 2002, 8:3-4.
31. Murray P.V., O'Brien M.E., Sayer R., Cooke N., Knowles G., Miller A.C., et al. The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway. Lung Cancer 2003, 42:283-290.